Navigation Links
Thymoquinone induced oxidative stress targets highly aggressive prostate cancers
Date:6/1/2010

This release is available in Chinese.

Researchers at the Tulane University School of Medicine, in New Orleans, LA, have demonstrated that thymoquinone (TQ) a major component of black seed oil (Nigella sativa) can suppress the growth of several aggressive prostate cancer (PCa) cell lines, in vitro. Although previous studies have shown the anti-proliferative effects of TQ in different types of cancers, the molecular mechanism of this effect of TQ had not been delineated. Since TQ has a structure similar to ubiquinone, a component of the mitochondrial coenzyme-Q (co-Q) complex, the effect of TQ on free oxygen radical production was investigated. These scientists showed exposure to TQ (20 100 M) caused a rapid induction of reactive oxygen species (ROS) generation in both LNCaP and C4-2B cells. A precipitous decrease in the level of glutathione (GSH) an intracellular small molecule antioxidant was also found to be responsible for the potent anti-cancer effects of TQ which could be inhibited by exogenous addition of N-acetyl cysteine (NAC) a GSH analog. Free oxygen radicals are often used as second messengers for mitogenic signaling in tumor cells where a critical balance in ROS generation and its rapid inactivation by antioxidants, can dictate cell growth or apoptosis. These investigators showed significant increases in several cell death (apoptosis) inducing factors, e.g. GAD45 and AIF-1, in TQ exposed PCa cells. This study appears in the June 2010 issue of Experimental Biology and Medicine.

Dr. Mondal stated that, "Complementary and alternative medicine (CAM) is becoming very important as an adjunct therapy in cancer patients, both to ameliorate the side effects of chemotherapy as well as to enhance their anti-tumor effects. The low side effect profiles of natural compounds is also an important aspect in their therapeutic utility as an adjunct to anti-tumor therapy. Indeed, in a previous publication (Exp Biol Med; (2009) Apr; 234(4) :442-53) we had shown that at lower concentrations (<5.0 M) TQ decreases ROS production and increases GSH levels in pancreatic beta-cells, which restored nelfinavir (an anti-HIV agent) induced deleterious effects on these cells. Our current findings suggest that the ROS generating effects of high concentrations of TQ (>20 M) may be of great advantage towards the development of novel anti-cancer therapeutics, especially against hormone-refractory prostate cancers which are much harder to treat."

The research team led by Dr. Krishna C. Agrawal (posthumously) included Dr. Sandeep Koka, previously a graduate student under Dr. Agrawal, and two other faculty members from Tulane University, Dr. Asim B. Abdel-Mageed and Dr. Debasis Mondal. These investigators successfully tested the hypothesis that TQ induced oxidative stress is responsible for its anti-proliferative effects in prostate cancer cells. Since black seed oil have been used in the middle eastern countries for hundreds of years, the investigators postulated that the active component TQ and possibly the oil itself, can be used effectively, either alone or as an adjunct to chemotherapy, to target highly aggressive prostate cancers.

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said "Koka et al have demonstrated that Thymoquinone efficiently killed hormone-dependent and hormone-independent prostate cancer cells. The mechanism appears to be that Thymoquinone induces oxidative stress and suppresses GSH levels. This suggests that oxidative stress may lead to decreased tumor growth and increased cell death in highly aggressive forms of prostate cancer."


'/>"/>

Contact: Dr. Debasis Mondal
dmondal@tulane.edu
504-988-4668
Society for Experimental Biology and Medicine
Source:Eurekalert

Related biology news :

1. HIV-1 protease inhibitor induced oxidative stress in pancreatic B-cells: thymoquinone protection
2. Folate prevents alcohol-induced congenital heart defects in mice
3. Cerner and ISAEC to collaborate on genetic studies of drug-induced serious adverse events
4. Gene silencing may be responsible for induced pluripotent stem cells limitations
5. Novel strategy for generating induced pluripotent stem cells for clinical use is safe and efficient
6. Induced neural stem cells: Not quite ready for prime time
7. Tummy troubles -- gastrin key in bacterial-induced stomach cancer
8. Simple drug treatment may prevent nicotine-induced SIDS: Study
9. Researchers engineer metabolic pathway in mice to prevent diet-induced obesity
10. International Serious Adverse Events Consortium announces initial study results in its global research collaboration to identify genetic markers related to drug induced liver injury
11. Did the North Atlantic fisheries collapse due to fisheries-induced evolution?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... ... April 20, 2017 , ... Husson University will be ... growing body of knowledge during its Eighth Annual Research and Scholarship Day ... Darling Atrium. During the event, undergraduates, graduate students, and faculty members from all ...
(Date:4/20/2017)... ... April 20, 2017 , ... Parallel6™ , the leader in mClinical™ ... that they were named one of the 2017 Top 10 eClinical Trial Management ... the pharmaceutical industry. , “We take pride in honoring Parallel6 as one of the ...
(Date:4/20/2017)... -- For today, Stock-Callers.com redirects investors, attention to ... clinical research aimed at treating diseases and medical conditions. Under ... Inc. (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), and ZIOPHARM ... our complimentary research reports on these stocks now at: ... http://stock-callers.com/registration ...
(Date:4/19/2017)... ... April 18, 2017 , ... Optofluidics today announced ... comes after the company changed focus to making analytical tools for biopharmaceutical quality ... new technology,” says CEO Robert Hart. Founders Bernardo Cordovez, Robert Hart and David ...
Breaking Biology Technology: